Quantcast

Latest PTC Therapeutics Stories

2009-08-10 07:00:00

SOUTH PLAINFIELD, N.J., Aug. 10 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) The collaboration began in March of 2006 based on PTC's HCV efforts that...

2009-06-15 07:00:00

- Funding supports continued focus on rare disorders - SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S. Department of Defense Neurofibromatosis Research Program has awarded an $822,345 grant to support a new open-label Phase 2 clinical trial of PTC's product candidate PTC299 in neurofibromatosis type 2 (NF2), a rare genetic tumor. Separately,...

2009-06-01 07:00:00

SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) "We are delighted to welcome Clare to our...

2009-02-03 08:47:24

A study by National Institutes of Health (NIH) researchers has revealed surprising new insights into the process used to initially identify an experimental drug now being tested in people with cystic fibrosis and muscular dystrophy. Researchers emphasized that the clinical implications of their findings are unclear, but said the results suggest more work may be needed to make sure the screening process to select promising agents was not flawed by its effects on a firefly enzyme used as a...

2009-02-03 07:00:00

- Ataluren designated as generic name for PTC124 - SOUTH PLAINFIELD, N.J., Feb. 3 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has successfully completed patient enrollment of its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Accrual was completed two months ahead of schedule. The company also announced today that PTC124 has been issued the generic name, ataluren. (Logo:...

2008-10-24 09:00:07

SOUTH PLAINFIELD, N.J. and ORLANDO, Fla., Oct. 24 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle SermetGaudelus, M.D.,...

2008-09-30 09:01:00

SOUTH PLAINFIELD, N.J., Sept. 30 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced promising findings in patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) at the 13th International World Muscle Society (WMS) Congress. Results from an observational study assessing the utility of the 6-minute walk test (6MWT) as a primary outcome measure in trials of treatment for DMD/BMD showed that the 6MWT clearly differentiates boys with DMD from healthy boys, especially when adjusted...

1af816e062695201b0bb43d6c490c1901
2008-08-21 09:20:00

A federal judge has ordered PTC Therapeutics to provide an experimental drug to a 16-year old Minnesota boy who has Duchenne muscular dystrophy, a rare terminal form of the genetic, degenerative disease that mostly affects young boys. U.S. District Judge William J. Martini heard arguments on Tuesday, and ruled Wednesday as Jacob Gunvalson sat in a wheelchair next to one of his lawyers, with his parents sitting nearby. Those who suffer from Duchenne muscular dystrophy typically die in their...

2008-07-28 09:01:47

SOUTH PLAINFIELD, N.J., July 28 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that the company was awarded the Art of Industry Partnership Award by the Genetic Alliance. Genetic Alliance presents the Art of Listening, Art of Advocacy, and Art of Industry Partnership Awards annually. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) "The Art of Industry Partnership Award honors a for-profit company that models the benefits of creative partnerships between...

2008-07-17 09:01:20

CAMBRIDGE, Mass. and SOUTH PLAINFIELD, N.J., July 17 /PRNewswire- FirstCall/ -- Genzyme Corporation and PTC Therapeutics, Inc. (PTC) today announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations. Under the terms of the agreement, PTC will commercialize PTC124 in the United States and Canada, and Genzyme will commercialize the treatment in all other...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related